Andrew Cittadine insider trades

Open-market stock purchases and sales by Andrew Cittadine, Chief Operating Officer at Monopar Therapeutics, from SEC Form 4 filings since Jun 1, 2021.

Recent trades

DateStockTradeValue
Sep 30, 2026MNPR Monopar TherapeuticsBought (not open market)—
Sep 30, 2026MNPR Monopar TherapeuticsSold (not open market)$155K
Sep 30, 2026MNPR Monopar TherapeuticsBought (not open market)—
Jun 30, 2026MNPR Monopar TherapeuticsBought (not open market)—
Jun 30, 2026MNPR Monopar TherapeuticsSold (not open market)$214K
Jun 30, 2026MNPR Monopar TherapeuticsBought (not open market)—
Mar 31, 2026MNPR Monopar TherapeuticsSold (not open market)$86.1K
Mar 31, 2026MNPR Monopar TherapeuticsBought (not open market)—
Dec 31, 2025MNPR Monopar TherapeuticsSold (not open market)$123K
Dec 31, 2025MNPR Monopar TherapeuticsBought (not open market)—
Dec 2, 2025MNPR Monopar TherapeuticsBought (not open market)—
Dec 2, 2025MNPR Monopar TherapeuticsBought (not open market)—

Companies traded

  • MNPR Monopar Therapeutics: 12 buys, last Sep 30, 2026

Get free alerts when Andrew Cittadine files a new trade →